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Abstract
Background: Non-steroidal anti-inflammatory (NSAID) medications are a common cause of reported adverse drug
side-effects. This study describes the prevalence of non-steroidal anti-inflammatory (NSAID) use (other than low-
dose aspirin) and the presence of co-existing relative contraindications to NSAID use and chronic conditions in a
representative population sample.
Methods: Data were analysed from 3,206 adults attending first follow-up of the North West Adelaide Health Study
(NWAHS) in 2004 - 2006, a longitudinal representative population study. Medications were brought into study clinic
visits by participants. Clinical assessment included measured blood pressure, kidney function, serum cholesterol,
blood glucose. Questionnaires assessed demographics, lifestyle risk factors, physician-diagnosed chronic conditions.
Data were weighted to census measures by region, age group, gender, and probability of selection in the
household, to provide population representative estimates. Pearson’s Chi-square tests determined significant
differences in proportions. Multiple logistic regression was used to examine associations of socio-demographic
characteristics with use of NSAIDs.
Results: Of 3,175 participants, 357 (11.2%), and 16% of those aged > 55 years, reported using either non-specific
NSAIDs or COX-2 inhibitors, other than low-dose aspirin. Among people using NSAIDs, 60.8% had hypertension,
30.8% had Stage 3 or higher chronic kidney disease, 17.2% had a history of cardiovascular disease (CVD) and 20.7%
had a > 15% 10-year CVD risk. The prevalence of NSAID use among people with hypertension was 16%, with
kidney disease 15.9%, and a history of CVD 20.0%. Among people taking diuretics, 24.1% were also taking NSAIDs,
and of those taking medications for gastro-esophageal reflux, 24.7% were on NSAIDs. Prescription-only COX-2
inhibitors, but not other NSAIDs, were used more by people > 75 years than by 35-54 year olds (OR 3.7, 95% CI
2.0, 6.7), and also were more commonly used by people with hypertension, cardiac and kidney disease.
Conclusions: There is a high prevalence of current NSAID use among groups at-risk for significant drug-related
adverse events or who have major chronic conditions that are relative contraindications to NSAID use. Assessment
of absolute risks regarding cardiovascular and kidney disease need to take into account use of medications such as
NSAIDs. The potential to make a substantial impact on chronic disease burden via improved use of NSAIDs is
considerable.
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Background
Non-steroidal anti-inflammation drugs (NSAIDs) are one
of the most common causes of reported serious adverse
reactions to drugs, with those involving the upper gastro-
intestinal tract (GIT) [1], the cardiovascular system [2,3]
and the kidneys being the most common [2,3]. Much of
the focus on NSAID adverse effects has been on GIT
consequences, with good reason. A US study found the
rate of deaths from NSAID-related GIT adverse effects is
higher than that found from cervical cancer, asthma or
malignant melanoma [4]. Significant deterioration in
blood pressure [5], development of chronic heart failure
(CHF) [6] and serious cardiovascular events can also
occur with a number of NSAIDs [7]. Risk is increased
among the elderly and those with co-morbidities [2,3]. It
has been suggested that the “burden of illness resulting
from NSAID-related CHF may exceed that resulting
from GIT damage” [6]. Recent evidence from a Danish
population study suggests that cardiovascular mortality is
increased among people without a prior history of car-
diac disease by NSAIDs, particularly diclofenac and ibu-
profen [8]. However, the baseline cardiovascular risk of
people in this study was not reported.
NSAIDs are implicated in rapid deterioration of renal
function [9,10], so national guidelines recommend the
avoidance of nephrotoxic drugs (including NSAIDs) in
people with chronic renal impairment [11].
Few studies in Australia have examined the frequency
of NSAID use among population groups at-risk for
adverse events or significant drug interactions. An audit
of rural general practices in Queensland found risk fac-
tors for NSAID-related adverse events (mostly older age,
hypertension and previous peptic ulcer disease) in 65.1%
of patients prescribed COX-2 inhibitors [12]. A claims
database analysis found use of NSAIDs in around 15%
of those taking diabetes medications [13]. These studies
have been unable to assess the effect of NSAIDs on
measures such as blood pressure or cardiac events in
these at-risk groups, particularly post-October 2004
when rofecoxib was withdrawn from the market. The
aim of this paper was to describe in a representative
population sample the prevalence of NSAID use (other
than low-dose aspirin), including differential use of
COX-2 inhibitors and non-specific NSAIDs (ns-NSAID)
and the presence of co-existing contraindications to
NSAID use and chronic conditions (including cardiac/
cerebrovascular disease, hypertension, chronic kidney
disease, diabetes, and high 10 year-risk for cardiovascu-
lar disease).
Methods
The NWAHS is a representative biomedical population
study of people aged ≥ 18 years randomly selected from
the electronic white pages telephone directory and living
in the north western suburbs of Adelaide, South Austra-
lia. The distribution of social indicators is representative
of the community profile of Adelaide [14]. The methods
for NWAHS [14] and the ability of these methods to
achieve an unbiased population-based sample have been
described previously [15]. In 2000 - 02, 4,060 people
attended the clinic for biomedical examination, includ-
ing surveys and clinical measurements of blood pres-
sure, height, weight, waist and hip circumference, fasting
glucose and lipid levels [14]. In 2004-2006 all partici-
pants were recontacted, with 3,522 completing inter-
views (86.7%), of which 3,206 (79.0%) attended for clinic
assessment, 120 (3.0%) died or were too ill to attend, 92
(2.3%) were unable to be contacted, and 326 (8.0%)
declined to participate. Compared with those who did
not complete reassessment in the clinic, persons who
remained in the study were not significantly different
across the study variables in terms of demographic char-
acteristics or disease distribution. This analysis was con-
ducted in 3175 subjects who provided medication data.
Information was collected on health behaviours
(smoking, alcohol use), doctor diagnosed health condi-
tions, symptoms of joint pain (in at least one of the fol-
lowing sites - foot, knee, hip, hand, shoulder), health
service utilization and demographics. All current medi-
cation use was recorded as dose, brand, type and usage
pattern of all medications including prescription, over-
the-counter and complementary medications that parti-
cipants were currently using and were presented at the
clinic visit. The study was approved by the North West
Adelaide Health Service institutional ethics committee,
and all subjects gave written informed consent.
Risk factor and Chronic Disease definitions
Hypertension: either systolic ≥ 140 mm Hg and or dia-
stolic ≥ 90 mm Hg, self-reported physician diagnosis or
on medication. High cholesterol: fasting total cholesterol
≥ 5.5 mol/l. Coronary Heart Disease (CHD): self-
reported physician diagnosed myocardial infarction or
angina. Stroke: self-reported physician-diagnosed stroke
or cerebrovascular event. Diabetes: fasting blood glucose
≥ 7.0 mmol/l, self-reported physician diagnosis of dia-
betes, or treatment for diabetes. Chronic kidney disease:
Glomerular filtration rate (GFR) was calculated using
the Cockcroft-Gault equation and kidney disease was
defined as: GFR < 60 ml/min/1.73 m2, or GFR > 60 and
proteinuria and was defined as Stage 3 or higher (GFR <
60), according to national guidelines [11]. Joint pain:
doctor diagnosed conditions (including arthritis
[osteoarthritis, rheumatoid arthritis or other arthritis])
and undiagnosed joint pain was defined as pain in at
least one site that had not been previously classified by
a doctor. High risk for Cardio-vascular disease (CVD):
10-year risk of > 15% for CHD for people aged 35-74
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years, without a prior history of CHD or stroke, using
Framingham Heart Study functions. High risk was based
on 15% 10-year CHD risk as it has been shown that the
risk of combined CVD (risk of CHD plus stroke/transi-
ent ischemic attack) may be obtained by multiplying the
estimated 10-year risk of CHD by 4/3 (i.e., 15% risk of
CHD = 20% risk of CVD) 16. The probability that a risk
of CHD > 15% would identify risk of combined CVD >
20% has been shown to be 91% in white people [16].
Statistical analysis
Data were weighted to the 1999 Estimated Residential
Population and 2001 Census for South Australia by
region, age group, gender, and probability of selection in
the household, to provide population representative esti-
mates [17]. Data were analysed using the Statistic Pack-
age for the Social Sciences (SPSS version 15.0; SPSS,
Chicago, IL). Pearson’s Chi-square tests determined sig-
nificant differences in proportions. Multiple logistic
regression models were developed to describe associa-
tions of socio-demographic characteristics with use of i)
non-specific NSAIDs (ns-NSAID), other than low-dose
aspirin, ii) COX-2 inhibitors, iii) all NSAIDs, adjusted
for age, sex, education level, employment status and
receipt of government benefits.
Results
The demographic profile of cohort participants has
been previously published [14]. Table 1 shows the
prevalence and multivariable associations for reported
NSAID use in various demographic categories.
NSAIDs were used by 357 (11.2%) of adults, 147
(9.8%) males and 210 (12.6%) females, and ranged
from 3.6% use in 20-34 year olds to 17.9% among
over 75 year olds. Among the 176 people using ns-
NSAIDs, naproxen was used by 39.8%, diclofenac by
39.8%, and ibuprofen by 11.9%. Of these, there were
38 who exclusively purchased medication over-the-
counter (ibuprofen 31 of 51 users; naproxen 7 of 21),
i.e. 21.6% of ns-NSAID users purchased these only
over-the-counter. In multivariable analyses, COX-2
inhibitors were used 3.7 times more often by those
aged 75 years and older than in 35 to 54 year olds
(Table 1). Rofecoxib use was reported by 31 (0.98%)
people. There was no association between advancing
age and use of ns-NSAIDs.
Table 1 Prevalence [% (n)] of non-steroidal anti-inflammatory drug (NSAID) use and multivariable adjusted odds ratios







% (n) OR (95% CI) % (n) OR (95% CI) % (n) OR (95% CI)
Sex
Male 4.8 (73) 1.0 (ref) 5.0 (76) 1.0 (ref) 9.8 (147) 1.0 (ref)
Female 6.2 (103) 1.2 (0.9-1.7) 6.7 (111) 1.5 (1.03-2.0) 12.6 (210) 1.3 (1.04-1.7)
Age
20-34 3.3 (10) 0.7 (0.4-1.4) 0.3 (1) 0.13 (0.02-0.98) 3.6 (11) 0.5 (0.3-0.98)
35-54 4.8 (60) 1.0 (ref) 2.3 (29) 1.0 (ref) 6.9 (87) 1.0 (ref)
55-74 6.5 (78) 0.9 (0.6-1.4) 9.1 (109) 3.1 (1.9-5.1) 15.4 (184) 1.6 (1.2-2.3)
75+ 6.7 (28) 0.8 (0.4-1.5) 11.5 (48) 3.7 (2.0-6.7) 17.9 (75) 1.7 (1.1-2.6)
Education
High school or less 6.2 (100) 1.0 (ref) 7.0 (113) 1.0 (ref) 13.1 (211) 1.0 (ref)
Diploma/certificate/trade 5.4 (62) 1.0 (0.7-1.4) 5.2 (59) 1.1 (0.7-1.5) 10.4 (119) 1.0 (0.8-1.3)
University degree 3.4 (14) 0.7 (0.4-1.2) 3.6 (15) 1.2 (0.7-2.2) 6.5 (27) 0.8 (0.5-1.3)
Employment
Full time 3.2 (36) 1.0 (ref) 2.2 (25) 1.0 (ref) 5.1 (58) 1.0 (ref)
Part time/casual 6.7 (35) 1.9 (1.1-3.1) 3.8 (20) 1.1 (0.6-2.1) 10.3 (54) 1.6 (1.1-2.4)
Unemployed 4.2 (3) 1.01 (0.3-3.5) 5.6 (4) 1.3 (0.4-4.1) 9.9 (7) 1.2 (0.5-3.0)
Home duties 5.2 (20) 1.2 (0.6-2.4) 6.8 (26) 0.9 (0.5-1.9) 11.9 (46) 1.2 (0.7-1.9)
Retired 7.7 (72) 2.0 (1.04-3.7) 10.5 (98) 1.2 (0.6-2.3) 18.2 (169) 1.7 (1.05-2.7)
Government benefit †
No 4.2 (77) 1.0 (ref) 2.8 (51) 1.0 (ref) 6.8 (125) 1.0 (ref)
Yes 7.6 (99) 1.4 (0.9-2.1) 10.3 (134) 1.9 (1.2-3.1) 17.7 (230) 1.6 (1.2-2.3)
*n = 11 missing data for income, employment, and government benefit
**6 participants were using both COX-2 and NSAIDs
† Government benefit includes all pensions or benefits but not including family allowance.
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Among those people using NSAIDs, 61% had hyper-
tension, with 41% reported concurrent use of anti-
hypertensive medication (Table 2). Thirty-one percent
of people taking NSAIDs had Stage 3 or higher
chronic kidney disease. Cardiac disease, hypertension
and renal disease were relatively more common among
people using COX-2 inhibitors than those using ns-
NSAIDs, as was the use of medications to treat these
conditions.
Of the overall sample, n = 1697 (42%) 1819 (45%) had
one or more of the identified chronic conditions where
use of NSAIDs is contraindicated or were at high-risk
of adverse events (i.e. cardiovascular disease, cerebrovas-
cular disease, chronic kidney disease, hypertension,
high-risk for cardiovascular disease). Among the n =
357 with NSAID use, 246 (69%) 274 (77%) had one or
more contraindications, including 141 (75%) who use
COX-2 inhibitors, and 109 (62%) of those taking ns-
NSAIDs. If anti-reflux medications are included as a
relative contra-indication, these numbers rise to 274
(77%) of all NSAID users, with 274 (84%) of COX-2
inhibitor users, and 121 (69%) of those using ns-
NSAIDs, with 1819 (45%) of the population with a rela-
tive contra-indication.
NSAID use was common among people with chronic
conditions (Table 3). Sixteen percent of all people with
uncontrolled hypertension and 16% with kidney disease
were using NSAIDs, as were 20% of people with cardio-
vascular disease. Around a quarter taking either diure-
tics (24.1%) or acid-lowering medication (24.7%)
reported NSAID use. Among people with joint pain not
diagnosed as arthritis NSAID use was much less com-
mon, and COX-2 inhibitor use was uncommon. People
with cardiac disease, hypertension and renal disease
more commonly used COX-2 inhibitors than ns-
NSAIDs. People taking anti-hypertensives, diuretics and
medications for gastro-esophageal reflux more com-
monly used COX-2 inhibitors than ns-NSAIDs.
Discussion
We have shown a high prevalence of current NSAID use
among groups at-risk for significant adverse drug-related





No Yes p No Yes No Yes
Chronic conditions, % (n)
Joint pain
Diagnosed as arthritis 23.4 (649) 70.8
(247)
< 0.01 26.9 (796) 57.5
(100)
< 0.01 25.3 (745) 83.4
(151)
< 0.01
Not diagnosed as arthritis 39.4 (1095) 22.6 (79) 37.8
(1117)
32.8 (57) 39.0 (1151) 12.7 (23)
Cardiovascular disease/stroke 8.7 (240) 17.2 (60) < 0.01 9.4 (276) 13.8 (24) 0.05 9.0 (264) 20.0 (36) < 0.01
MI/angina 6.5 (182) 12.0 (42) < 0.01 7.0 (208) 9.2 (16) 0.28 6.7 (198) 14.4 (26) < 0.01
> 15% 10 year CVD risk 14.9 (324) 20.7 (56) 0.01 15.4 (355) 17.9 (25) 0.44 15.1 (348) 23.7 (32) < 0.01




52.8 (93) < 0.01 41.0 (1226) 68.4
(128)
< 0.01
Kidney disease** 20.6 (576) 30.8
(109)
< 0.01 21.6 (644) 23.4 (41) 0.58 20.8 (616) 37.3 (69) < 0.01
Primary care provider visits in previous
year
0 7.9 (219) 2.3 (8) < 0.01 7.4 (220) 4.0 (7) < 0.01 7.7 (226) 0.6 (1) < 0.01




32.2 (56) 51.9 (1530) 26.0 (47)









Anti-hypertensives 26.6 (749) 40.9
(146)
< 0.01 27.9 (836) 33.5 (59) 0.11 27.0 (806) 47.6 (89) < 0.01
Diuretics 3.6 (101) 9.0 (32) < 0.01 4.1 (123) 5.7 (10) 0.31 3.7 (110) 12.3 (23) < 0.01
ACE inhibitors 11.3 (319) 12.0 (43) 0.69 11.2 (336) 14.8 (26) 0.15 11.5 (344) 9.6 (18) 0.43
Gastro-esophageal reflux 12.3 (347) 31.9
(114)
< 0.01 14.0 (419) 23.9 (42) < 0.01 12.9 (386) 40.1 (75) < 0.01
*Hypertension: systolic ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg or use of anti-hypertensive medication.
**Kidney disease: GFR < 60 ml/min/1.73 m2, GFR > 60 and proteinuria.
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events or who had major chronic conditions that are
relative contraindications to NSAID use. Around three-
quarters of people using NSAIDs have one or more of
cardiovascular disease, hypertension or chronic kidney
disease. These include over half of people reporting
NSAID use with hypertension and nearly one-third of
reported users had Stage 3 or higher chronic kidney dis-
ease. A fifth of all people with cardiovascular disease
report NSAID use. This usage was not driven by isola-
tion from health care services, as over two-thirds of
NSAID users reported 5 or more GP visits in the past
year.
Recent evidence that cardiovascular mortality is
increased by some NSAIDs among people without a
prior history of cardiac disease [8] highlights the impor-
tance of examining patterns of NSAID use and out-
comes of use at a population level. COX-2 inhibitors
can only be obtained by prescription, while some ns-
NSAIDs can be purchased over-the-counter without a
prescription (albeit at lower doses than possible via
prescription), although this was a minority of users did
this exclusively in our study. There were clear differ-
ences in the trends of use of ns-NSAIDs and COX-2
inhibitors with socio-demographic characteristics exam-
ined. COX-2 inhibitor use was seen more commonly in
people with cardiac disease, hypertension and renal dis-
ease compared with ns-NSAID use. People on medica-
tions to treat hypertension or cardiac disease more
commonly used COX-2 inhibitors than ns-NSAIDs.
This suggests different considerations are operational
for both patients and their doctors across clinical and
demographic categories in determining NSAID use.
Roughead et al found that following the introduction of
COX-2 inhibitors onto the Australian market there was
a large increase in overall NSAID use, with subsequent
decline when rofecoxib was withdrawn. Prescribing
trends were similar in people also taking diabetes medi-
cations or ACE inhibitors to the rest of the population
[13]. While our data are not conclusive, it is consistent
with the notion that putative GIT safety is taken into
Table 3 Prevalence of NSAID use [%, (n)] among people with various chronic conditions and medication use






Joint pain No 2.2 (23) < 0.01 1.6 (17) < 0.01 0.7 (7) < 0.01
Yes
Diagnosed as arthritis 27.6 (247) 11.2 (100) 16.9 (151)
Not diagnosed as arthritis 6.7 (79) 4.9 (57) 2.0 (23)
Cardiovascular disease/stroke No 10.2 (289) < 0.01 5.3 (150) 0.05 5.1 (144) < 0.01
Yes 20.0 (60) 8.0 (24) 12.0 (36)
MI/angina No 10.6 (308) < 0.01 5.4 (158) 0.28 5.3 (155) < 0.01
Yes 18.8 (42) 7.1 (16) 11.6 (26)
> 15% 10 year CVD risk No 10.4 (214) 0.01 5.6 (115) 0.44 5.0 (103) < 0.01
Yes 14.7 (56) 6.6 (25) 8.4 (32)
Hypertension* No 7.7 (140) < 0.01 4.6 (83) < 0.01 3.2 (59) < 0.01
Yes 16.0 (217) 6.9 (93) 9.5 (128)
Kidney disease** No 9.9 (245) < 0.01 5.4 (134) 0.58 4.7 (116) < 0.01
Yes 15.9 (109) 6.0 (41) 10.1 (69)
Primary care provider
visits in previous year
None 3.5 (8) < 0.01 3.1 (7) < 0.01 0.4 (1) < 0.01
1-4 6.5 (103) 3.6 (56) 3.0 (47)
≥ 5 18.0 (239) 8.4 (111) 10.0 (133)
Medication use
Anti-hypertensives No 9.3 (211) < 0.01 5.1 (117) 0.11 4.3 (98) < 0.01
Yes 16.3 (146) 6.6 (59) 9.9 (89)
Diuretics No 10.7 (325) < 0.01 5.5 (166) 0.31 5.4 (164) < 0.01
Yes 24.1 (32) 7.5 (10) 17.3 (23)
ACE inhibitors No 11.2 (314) 0.69 5.3 (150) 0.15 6.0 (169) 0.43
Yes 11.9 (43) 7.2 (26) 5.0 (18)
Gastro-esophageal reflux No 9.0 (243) < 0.01 4.9 (134) < 0.01 4.1 (112) < 0.01
Yes 24.7 (114) 9.1 (42) 16.3 (75)
*Hypertension: systolic ≥ 140 mm Hg and/or diastolic ≥ 90 mm Hg or use of anti-hypertensive medication.
**Kidney disease: GFR < 60 ml/min/1.73 m2, GFR > 60 and proteinuria.
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consideration when prescribing whilst cardiac disease,
renal function and blood pressure have less influence on
management decisions [13,18]. As COX-2 inhibitors are
a prescription only medication, and most ns-NSAID use
was via prescription, our results suggest that the risks of
COX-2 inhibitors for cardiac disease, hypertension or
renal disease are regarded as acceptable or are ignored
by many clinicians. Rofecoxib was withdrawn early in
the study period and few people reported its use. Thus
our conclusions are driven by NSAID use other than
that of rofecoxib.
Although NSAIDs are some of the most commonly
used medications, their safe and effective management is
complex. Shorter clinic visits have been associated with
unnecessary NSAID prescribing which was related to a
lesser likelihood that relative contraindications to
NSAID therapy were assessed during these brief visits
[19]. This problem may be confounded when caring for
socially disadvantaged patients with complex biomedical
and psychosocial problems and multiple barriers to care
placing great demands onto a 10-15 minute primary
care visit [20]. We found significantly increased use of
NSAIDs among people receiving government benefits
and part-time workers in the multivariable analyses,
which may reflect social disadvantage.
Studies suggest increased clinician knowledge has
minimal [20] or no effect [21] on NSAID prescribing. In
one study, no association was found between knowledge
of NSAID therapy and suboptimal management [20]. A
targeted education intervention had only a small effect
on prescriber’s actions in NSAID use in one study [21].
Other explanations may include differences between
doctors in their perceptions of the importance of treat-
ment risks or in the expected benefits of drug therapy
[22], particularly given the conflicting publicity sur-
rounding such issues as cardiovascular risk associated
with NSAID use. For a variety of reasons clinicians may
not be aware of contraindications to NSAID use in indi-
vidual patients, for example patients may see a number
of general practitioners and specialists for their care.
Patient attitudes and knowledge as well as willingness to
ask questions of clinicians will have impact on NSAID
use. It may be that some NSAID users are well aware of
the potential harms but use NSAIDs because they get
relief from pain that they can’t obtain through other
means. However, many patient’s lack of awareness of
NSAID toxicity with US data demonstrating that among
patients with knee osteoarthritis (OA) 54% were una-
ware of NSAID toxicity and 80% unaware of COX-2
toxicity [23]. These results are particularly problematic
given the wide availability of over-the-counter (OTC)
NSAIDs. In contrast, a study of patient preferences in
older patients with knee OA determined that most were
willing to forgo treatment effectiveness for a lower risk
of adverse effects [24]. A recent review of published stu-
dies in OA concluded that for every ten patients treated
with paracetamol instead of a NSAID for OA, only one
patient would discontinue treatment due to lack of effi-
cacy, implying that 9 out of ten patients would continue
with paracetamol [25]. Given the scope of the problem
identified in our study, efforts to improve the health lit-
eracy of the community [26] have the potential to have
a substantial impact on the burden-of-illness and costs
of NSAIDs. The more widespread use of tools or deci-
sion-aids to assist patient decision-making may be a
potential solution [27]. However research to assess the
impact of sophisticated decision-support software which
could present individually calculated risks against likely
pain benefits from NSAIDs to patients and doctors is
needed.
Our study is limited to one urban region and it is pos-
sible substantial regional differences in patterns of medi-
cation use may occur across Australia. Recent US data
has shown considerable geographical variation in pre-
scription of NSAIDs to elderly people with chronic
renal disease [28]. However, other Australian studies
have found similar patterns in national and regional
data, including one recent study which found that use of
ns-NSAIDs, COX-2 inhibitors and paracetamol overall
among concession beneficiaries was comparable in Aus-
tralia and Queensland [29]. Our data on medication use
relies on participants bringing their medication to the
study clinic. However, both prescription-based data and
general practitioner databases may underestimate the
use of NSAIDs as unreported OTC usage is common.
Similarly general practitioner databases may also under-
estimate NSAID use, as patients may not report use of
OTC medications to doctors. In one US study, almost
one in five respondents did not report use of an NSAID
to clinical staff, including 8% who reported daily use.
For 22% of respondents, they did not think the medica-
tions were important enough to list, while 30% cited the
fact that the drugs were not prescribed by a physician
[30]. This reflects a common misperception that these
medications are insignificant or benign when actually
their chronic use, particularly among the elderly and
those with conditions such as arthritis, is linked to ser-
ious and potentially fatal adverse effects [31].
Our survey was limited to households with listed tel-
ephone numbers, but as 97% of the households in the
region had telephones during the study period, and the
demographic characteristics were representative of the
population of profile of Adelaide overall [14], the
extent of any bias is likely to be small. Underestima-
tion of cardiac history from self-report in our sample
may also have attenuated the relationship with
NSAIDs. However, studies from community popula-
tions have found self-reported cardiac events and
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stroke to be accurate [31]. Framingham risk equations
tend to overestimate risk in the affluent elderly and
underestimate in the poorer young. Loss to follow-up
may also bias our findings. The strength of this study
is the large representative population sample with
known probability of selection, measurements of other
known chronic disease risk factors, and low drop-out
rate in follow-up, especially in people over 45 years
who are more likely to be at risk for chronic disease
and use of NSAIDs, and that participants brought in
all medications they were taking (including both pre-
scribed and over-the-counter) and that usage was clari-
fied at the clinic visits.
Conclusions
There is a high prevalence of current NSAID use among
groups at-risk for significant drug-related adverse events
or who have major chronic conditions that are relative
contraindications to NSAID use. Assessment of absolute
risks regarding cardiovascular and kidney disease need
to take into account use of medications such as
NSAIDs. The potential to make a substantial impact on
chronic disease burden via improved use of NSAIDs is
considerable.
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